Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/2/2024 | $22.00 | Neutral | Goldman |
5/30/2024 | Sell → Neutral | Seaport Research Partners | |
2/28/2024 | $17.50 | Neutral → Sell | Seaport Research Partners |
12/14/2023 | Neutral | Seaport Research Partners | |
6/8/2022 | $8.00 | Underperform → Neutral | BofA Securities |
5/23/2022 | $7.00 | Mkt Perform | SVB Leerink |
12/10/2021 | $18.00 → $7.00 | Equal-Weight → Underweight | Morgan Stanley |
12/10/2021 | $33.00 → $12.00 | Buy → Neutral | Goldman Sachs |
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
PORTLAND, Ore., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) today reported results for the first quarter of fiscal 2025 ended November 30, 2024. The Company reported a loss per share from continuing operations of $(1.30) and a net loss of $(37) million in the first quarter of fiscal 2025, compared to ($0.64) and ($18) million, respectively, in the prior year first quarter, with the difference substantially driven by a detriment on income tax in the current quarter. Adjusted EBITDA was break-even in the first quarter of fiscal 2025, compared to $1 million in the prior year first quarter. Adjusted loss per share from continuing operations was $(1.33) in the firs
PORTLAND, Ore., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) announced that the Company will report financial results for its first quarter fiscal 2025 ended November 30, 2024 on Wednesday, January 8, 2025. The Company will host a webcast conference call to discuss the results at 11:30 a.m. Eastern Time on the same day. The webcast of the call and the accompanying slide presentation may be accessed on Radius Recycling's website at www.radiusrecycling.com/company/investors. The call will be hosted by Tamara Lundgren, Chairman and Chief Executive Officer, and Stefano Gaggini, Senior Vice President and Chief Financial Officer. About Radius Recycling, Inc. Radius Re
Significant Sequential Improvement in Operating and Financial Performance in Q4 Ferrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) today reported results for the fourth quarter and fiscal year ended August 31, 2024. The Company reported a net loss of $(16) million, or $(13) per ferrous ton, and a loss per share from continuing operations in the fourth quarter of fiscal 2024 of $(0.56), a significant improvement compared to the third quarter which included a material goodwill impairment charge. Adjusted EBITDA in the fourth quarter was $17 mi
SC 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)
SC 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)
SC 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)
PORTLAND, Ore., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) today announced the appointment of Marc Hathhorn as Executive Vice President and Chief Operating Officer, effective November 1, 2024. Hathhorn joins Radius from Peabody Energy Corporation (NYSE:BTU) and brings more than 30 years of leadership experience in the mining industry. Most recently, Hathhorn held the position of President--Global Operations at Peabody Energy Corporation (NYSE:BTU), overseeing 5,000 employees and 17 coal mines across the U.S. and Australia. Under Hathhorn's leadership, Peabody achieved multiple safety performance awards, exceeded environmental management and compliance goals, an
PORTLAND, Ore., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) announced that its Board of Directors has appointed Mauro Gregorio, the recently retired President of the Performance Materials & Coatings Division at Dow Inc. (NYSE:DOW), as a new independent director, effective November 1, 2024. Mr. Gregorio will serve on the Audit Committee and the Compensation and Human Resources Committee of the Board. Over his nearly 40-year career at Dow, Mr. Gregorio served in multiple roles, including leading the post-acquisition integration of Dow Corning, overseeing the company's feedstock and energy business unit, and serving as global Vice President for the Hygiene and Medi
Urges Stockholders to Vote "FOR" Radius' Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card Details Company's Significant Progress Since 2020, Under Refreshed Board and Management Team BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (NASDAQ:RDUS) today announced that it has filed its definitive proxy statement with the Securities and Exchange Commission ("SEC") for its upcoming Annual Meeting of Stockholders, which will be held online on July 8, 2022. Stockholders of record as of June 3, 2022, will be entitled to vote at the meeting. In c
Goldman initiated coverage of Radius Recycling with a rating of Neutral and set a new price target of $22.00
Seaport Research Partners upgraded Radius Recycling from Sell to Neutral
Seaport Research Partners downgraded Radius Recycling from Neutral to Sell and set a new price target of $17.50
PORTLAND, Ore., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) today reported results for the first quarter of fiscal 2025 ended November 30, 2024. The Company reported a loss per share from continuing operations of $(1.30) and a net loss of $(37) million in the first quarter of fiscal 2025, compared to ($0.64) and ($18) million, respectively, in the prior year first quarter, with the difference substantially driven by a detriment on income tax in the current quarter. Adjusted EBITDA was break-even in the first quarter of fiscal 2025, compared to $1 million in the prior year first quarter. Adjusted loss per share from continuing operations was $(1.33) in the firs
BOSTON, MA / ACCESSWIRE / January 2, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Pharmanovia the exclusive commercialization rights to abaloparatide, a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. The licensing agreement covers markets in the Asia Pacific region, specifically China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines. Abaloparatide is marketed in the U.S. by Radius u
PORTLAND, Ore., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ:RDUS) announced that the Company will report financial results for its first quarter fiscal 2025 ended November 30, 2024 on Wednesday, January 8, 2025. The Company will host a webcast conference call to discuss the results at 11:30 a.m. Eastern Time on the same day. The webcast of the call and the accompanying slide presentation may be accessed on Radius Recycling's website at www.radiusrecycling.com/company/investors. The call will be hosted by Tamara Lundgren, Chairman and Chief Executive Officer, and Stefano Gaggini, Senior Vice President and Chief Financial Officer. About Radius Recycling, Inc. Radius Re
10-Q - RADIUS RECYCLING, INC. (0000912603) (Filer)
8-K - RADIUS RECYCLING, INC. (0000912603) (Filer)
DEFA14A - RADIUS RECYCLING, INC. (0000912603) (Filer)
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-13) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/19/2022. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-10) with active ingredient ABALOPARATIDE has changed to 'Approval' on 12/22/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy
Submission status for RADIUS HEALTH INC's drug TYMLOS (SUPPL-10) with active ingredient ABALOPARATIDE has changed to 'Tentative Approval' on 10/28/2021. Application Category: NDA, Application Number: 208743, Application Classification: Efficacy